Skip To Main Content
Bydureon Pen on Muck Rack

Bydureon Pen

As seen in: RXLIST®, DrugPatentWatch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Bydureon Pen’s profile

Articles by Bydureon Pen

Side Effects, Uses, Dosage, Interactions, Warnings

|
By Keep Bydureon, If Bydureon, Bydureon Pen, BYDUREON Versus Sitagliptin
| RXLIST®
WARNING RISK OF THYROID C-CELL TUMORS Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether Bydureon causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined [see WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].
Open in Who Shared Issue with article?

BYDUREON PEN Loss of Exclusivity (LOE). When will the BYDUREON PEN patents expire, and when will generic BYDUREON PEN be available?

|
By Bydureon Pen
| DrugPatentWatch
BYDUREON PEN is protected by twenty-two US patents and five FDA Regulatory Exclusivities.
Open in Who Shared Issue with article?

How to Use a Bydureon Pen

|
By Bydureon Pen, Damaris Vega, Bydureon Single-Dose Injector
| wikiHow
We use cookies to make wikiHow great. By using our site, you agree to our cookie policy.Cookie Settings ✖ Download Article Download Article X This article was co-authored by Damaris Vega, MD. Dr. Damaris Vega is a board certified Endocrinologist. She graduated Magna Cum Laude from the Pontifical Catholic University of Puerto Rico with a BS in General Science and subsequently earned an MD from the Ponce School of Medicine, Ponce, PR.
Open in Who Shared Issue with article?

Drugs@FDA: FDA Approved Drug Products

|
By Bydureon BCise, Bydureon Pen
| U.S. Food and Drug Administration (FDA)
Actemra Tocilizumab INJECTABLE; INJECTION 125276 GENENTECH 05/17/2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf#page=41 Actemra Tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 GENENTECH 05/17/2018 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125276s116,125472s030lbl.pdf#page=41 Actemra Tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 GENENTECH 05/17/2018...
Open in Who Shared Issue with article?
Show More